Plain-English translation of NCT07305116 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called universal allogeneic CAR T-cell therapy targeting CD19 and BCMA in patients with autoimmune diseases. CAR T-cells are immune cells that have been modified in the laboratory to recognize and fight the B cells that are causing your autoimmune disease. The treatment involves receiving a single infusion of these modified cells after a short preparation with chemotherapy to make room for them in your body.
Autoimmune diseases like lupus, kidney disease, and vasculitis can be very difficult to treat with standard medications, and many patients don't respond well or cannot tolerate conventional therapies. This trial is exploring whether this new immune cell therapy might offer hope for people whose disease has resisted traditional treatment options.
You likely qualify if…
You likely don't qualify if…
If you are selected for this trial, you will first receive chemotherapy (cyclophosphamide) to prepare your body. Then you will receive a single infusion of the modified immune cells through an IV. After the infusion, you will have follow-up visits and testing at 12 weeks and 24 weeks to check for safety and how well the treatment is working. The study will carefully monitor you for any side effects and measure changes in your disease activity over time.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
The Children's Hospital of Zhejiang University School of Medicine
Enrollment target
~15 participants
Started
December 2025
Primary completion
December 2028
Age range
3 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jianhua Mao, PhD
The Children's Hospital of Zhejiang University School of Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.